Proteases/Proteasome

TY-51469 is an inhibitor of chymase (IC50s for simian and human chymases: 0.4 and 7.0 nM, respectively).

Setrobuvir (ANA-598) is an orally active non-nucleoside HCV NS5B polymerase inhibitor with inhibitory effects on de novo RNA synthesis and primer extension with

VRK-IN-1 is a potent and selective inhibitor of cowpox-associated kinase 1 (VRK1), which can be used in the study of neurological disorders.

2'-C-Methyladenosine from C. renalis inhibits HCV, NS5B RNA synthesis (IC50: 0.3, 1.9µM), and LRV1 in L. guyanensis, L. braziliensis.

MMP-2/MMP-9-IN-1: oral IV collagenase inhibitor; IC50: 0.24 μM (MMP-9), 0.31 μM (MMP-2); targets cancer.

Gemigliptin (LC15-0444) is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor(KD : 7.25 nM.)

DB04760: selective MMP-13 inhibitor, non-zinc-chelating, IC50=8nM, reduces paclitaxel neurotoxicity, anticancer.

Sovaprevir is a non-structural 3 (NS3) protease inhibitor with antiviral activity for the treatment of HCV infection.

Melagatran is an orally available, direct synthetic thrombin inhibitor that does not require endogenous cofactors other than thrombin.Cost-effective and quality-assured.

BILB-1941 (BILB-1941ZW) is an inhibitor of HCV NS5B polymerase and can be used in studies about HCV infection.

JNJ-10311795 (RWJ-355871) is an inhibitor of neutrophil elastase G and mast cell chymase, demonstrating significant anti-inflammatory effects.

CPA inhibitor (Carboxypeptidase inhibitor) is a potent carboxypeptidase A (CPA) inhibitor with a Ki of 0.32 μM.

AGPS-IN-2i inhibits alkylglycerol phosphate synthase, affecting ether lipid metabolism and reducing cancer cell migration and proliferation.

Uprifosbuvir is an inhibitor of uridine nucleotide analog HCV NS5B polymerase.

MMP2-IN-3 is a potent inhibitor of matrix metalloproteinases (MMP-2) (IC50: 31 μM).

TS-021 is a selective dipeptidyl peptidase 4 (DPP-4) inhibitor with antidiabetic activity for the study of type 2 diabetes.

UK-396082 is a TAFI inhibitor that inhibits Carboxypeptidase B and can be used in the study of thrombosis, atherosclerosis, cancer and fibrotic conditions.

CP-544439 is an inhibitor of matrix metalloproteinase-13, which has an effect on adipose tissue development.

Sirpiglenastat (DRP-104) is a glutamine antagonist, a prodrug of DON, with antitumor activity that acts by suppressing the adaptive immune system.

Lenacapavir (GS-6207) is the first HIV-1 capsid inhibitor approved by the U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada for the treatment of MDR HIV-1 infection.Cost-effective and quality-assured.

Etarotene (Arotinoid ethyl sulphone) is an ethylsulfonyl derivative of aloe acid with differentiation-inducing and potentially antitumor activity.Etarotene is a

BMS-929075 is an orally active HCV NS5B replicase (HCV NS5B replicase) palm site variant inhibitor with potency, high oral bioavailability and pharmacokinetic

Isatoribine(ANA245) free base is a potent TLR7 receptor agonist with anti-hepatitis C virus infection activity for the study of HCV infection.

PG-116800 (PG-530742) is a matrix metalloproteinase (MMP) inhibitor. PG-116800 can be used in studies about the treatment of osteoarthritis.

BAY-43-9695 is a non-nucleoside compound with anti-human cytomegalovirus (HCMV) activity. It is the major metabolite of BAY-38-4766.

BDCRB disrupts HCMV DNA maturation by altering terminase cleavage, extending packaging 30 kb until second site.

Dim16, a dual inhibitor of PCSK9/HMG-CoAR, demonstrates potent activity with an IC50 of 19 nM against PCSK9 and significantly impedes PCSK9-LDLR interaction

Mergetpa, a carboxypeptidase inhibitor, impedes the conversion of kinins and B2 receptor antagonists into metabolites devoid of the C-terminal arginine [1].

GSK-625433: Homochiral inhibitor blocks HCV genotypes 1a/1b polymerase.

Matrix metalloproteinase-3 (MMP-3), also known as stromelysin-1, is a critical enzyme involved in tissue remodeling and repair through its role in degrading extracellular matrix proteins, facilitating cell migration. This enzyme has been implicated in various physiological processes including vascular remodeling associated with aneurysm formation, wound healing, the progression of atherosclerosis, and tumor initiation. MMP-3 inhibitor VIII, a cell-permeable sulfonamide-based hydroxamic acid, effectively inhibits MMP-3 by binding to its active site (Ki = 23 nM), thus blocking its enzymatic activity. Additionally, this inhibitor has been demonstrated to suppress the activity of mouse macrophage metalloelastase MME/MMP-12, with an IC50 value of 13 nM, highlighting its potential utility in research on tissue remodeling and disease processes involving MMPs.

AZD-7295 (A-689) is an NS5A inhibitor that may be used to treat HCV infection.

ND-378 is a potent and selective inhibitor of MMP-2 with no inhibition on MMP-9 and MMP-14.

BMS-189664 is an inhibitor of thrombin.

MMP-7-IN-3 (compound 15) is a potent and selective MMP-7 inhibitor, inhibiting renal fibrosis in a unilateral ureteral obstruction mouse model.

MMP-145 is used as a protease inhibitor.

Neurodegenerative Disorder-Targeting Compound 1 is an inhibitor of calpain [1].

NS5A-IN-3 is a potent NS5A inhibitor with high efficacy against HCV 1b, good activity on 3a, and strong metabolic stability; superior to daclatasvir.

O-Benzoyl hydroxylamine exhibits properties as a dipeptidyl peptidase-IV (DPP-IV) inhibitor and demonstrates antidiabetic effects[1].

NS5A-IN-2, a potent inhibitor, is highly effective against HCV 1b and shows increased activity for GT 3a with good metabolic stability.

TP0556351: potent MMP2 inhibitor with 0.2 nM IC50, reduces collagen in pulmonary fibrosis mice.

ONO-4817 suppresses MMPs, limiting plaque progression and aortic hyperplasia in hyperlipidemic rabbits.

MDL 101146 is an orally active neutrophil elastase inhibitor.

GS-6620 is a HCV nonstructural protein 5B (NS5B) inhibitor.

Ro 32-7315 is a selective inhibitor of ADAM17.

KB-R7785 is a novel ADAM12/MMP inhibitor improving heart function and insulin sensitivity by blocking HB-EGF and TNF-alpha.

Z-FG-NHO-BzOME is a chemical compound functioning as a cysteine protease inhibitor, selectively targeting and inhibiting cathepsin B, cathepsin L, cathepsin S,

BAY-678: Oral selective human neutrophil elastase inhibitor; IC50: 20 nM; SGC-approved chemical probe.